<DOC>
	<DOCNO>NCT01665144</DOCNO>
	<brief_summary>Evaluate safety efficacy Siponimod ( BAF312 ) versus placebo variable treatment duration patient secondary progressive multiple sclerosis ( Core Part ) follow extended treatment open-label BAF312 obtain data long-term safety , tolerabiilty efficacy ( Extension Part ) .</brief_summary>
	<brief_title>Exploring Efficacy Safety Siponimod Patients With Secondary Progressive Multiple Sclerosis ( EXPAND )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>Prior history relapse remit MS SPMS define progressive increase disability least 6 month EDSS score 3.0 6.5 No relapse corticosteroid treatment within 3 month Women child bear potential must use reliable form contraception . Diagnosis Macular edema screen period Any medically unstable condition determine investigator . Unable undergo MRI scan Hypersensitivity study drug drug similar class Other protocol define inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Secondary Progressive Multiple Sclerosis</keyword>
</DOC>